{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:30:39Z","timestamp":1732037439752},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004634","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004634","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kowa"},{"name":"Algorithm"},{"name":"IONIS"},{"name":"Esperion"},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda"},{"name":"Boehringer Ingelheim"},{"name":"Resverlogix"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cerenis"},{"name":"Cipla"},{"name":"Mylan"},{"name":"Janssen"},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","cardiology.theclinics.com","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ccl.2017.12.002","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:24:28Z","timestamp":1522455868000},"page":"213-220","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lipids and Lipoproteins in Risk Prediction"],"prefix":"10.1016","volume":"36","author":[{"given":"Savvas","family":"Hadjiphilippou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2017.12.002_bib1","series-title":"Global Health Estimates 2015: Deaths by cause, age, sex, by country and by region, 2000\u20132015","year":"2016"},{"issue":"Suppl A","key":"10.1016\/j.ccl.2017.12.002_bib2","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary artery disease\u2013the Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can J Cardiol"},{"issue":"22","key":"10.1016\/j.ccl.2017.12.002_bib3","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.ccl.2017.12.002_bib4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2017.12.002_bib5","first-page":"1","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"9493","key":"10.1016\/j.ccl.2017.12.002_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"25\u00a0Suppl 2","key":"10.1016\/j.ccl.2017.12.002_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"9753","key":"10.1016\/j.ccl.2017.12.002_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"7659","key":"10.1016\/j.ccl.2017.12.002_bib9","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ccl.2017.12.002_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham heart study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2017.12.002_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccl.2017.12.002_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL-cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"issue":"8934","key":"10.1016\/j.ccl.2017.12.002_bib13","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ccl.2017.12.002_bib14","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Di Angelantonio","year":"2012","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ccl.2017.12.002_bib15","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2017.12.002_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jama.294.3.326","article-title":"Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for\u00a0cardiovascular disease in women","volume":"294","author":"Ridker","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ccl.2017.12.002_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2004.09.022","article-title":"Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals","volume":"179","author":"Rallidis","year":"2005","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.ccl.2017.12.002_bib18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.amjcard.2005.06.044","article-title":"Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction","volume":"96","author":"Farwell","year":"2005","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.ccl.2017.12.002_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non\u2013HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ccl.2017.12.002_bib20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ccl.2017.12.002_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2009.07.057","article-title":"Beyond low-density lipoprotein cholesterol respective contributions of non\u2013high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol\/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently health","volume":"55","author":"Arsenault","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2017.12.002_bib22","series-title":"NICE guidelines. Cardio cardiovascular disease: risk assessment vascular disease: risk assessment and reduction, including lipid and reduction, including lipid modification modification","year":"2014"},{"issue":"11","key":"10.1016\/j.ccl.2017.12.002_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ccl.2017.12.002_bib24","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","author":"Miller","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2017.12.002_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease 10 158 incident cases among 262 525 participants in 29 western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2017.12.002_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9726","key":"10.1016\/j.ccl.2017.12.002_bib27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ccl.2017.12.002_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and\u00a0cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2017.12.002_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2017.12.002_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.ccl.2017.12.002_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.ATV.8.3.207","article-title":"High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study","volume":"8","author":"Abbott","year":"1988","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"10.1016\/j.ccl.2017.12.002_bib32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and\u00a0cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9738","key":"10.1016\/j.ccl.2017.12.002_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ccl.2017.12.002_bib34","doi-asserted-by":"crossref","first-page":"e005549","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"9841","key":"10.1016\/j.ccl.2017.12.002_bib35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ccl.2017.12.002_bib36","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1161\/01.CIR.0000146339.57154.9B","article-title":"Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines","volume":"110","author":"Shai","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2017.12.002_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","article-title":"Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS)","volume":"101","author":"Gotto","year":"2000","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2017.12.002_bib38","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0002-9149(96)00863-6","article-title":"Baseline risk factors and their association with outcome in the west of Scotland coronary prevention study. The west of Scotland coronary prevention study group","volume":"79","year":"1997","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2017.12.002_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosissup.2004.08.030","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atheroscler Suppl"},{"issue":"4","key":"10.1016\/j.ccl.2017.12.002_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4158\/EP09064.RAR","article-title":"Refining lipoprotein assessment in diabetes: apolipoprotein B makes sense","volume":"15","author":"Ganda","year":"2009","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.ccl.2017.12.002_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/01.CIR.94.3.273","article-title":"Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Qu\u00e9bec Cardiovascular Study","volume":"94","author":"Lamarche","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2017.12.002_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the Europea","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.ccl.2017.12.002_bib43","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","article-title":"Lipoprotein management in patients with cardiometabolic risk. Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation","volume":"51","author":"Brunzell","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2017.12.002_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2017.12.002_bib45","article-title":"Effects of Anacetrapib in patients with atherosclerotic vascular disease","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9298","key":"10.1016\/j.ccl.2017.12.002_bib46","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ccl.2017.12.002_bib47","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/01.ATV.0000035521.22199.C7","article-title":"Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men","volume":"22","author":"Talmud","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.ccl.2017.12.002_bib48","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/clinchem\/44.11.2301","article-title":"Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies","volume":"44","author":"Craig","year":"1998","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.ccl.2017.12.002_bib49","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A\u00a0test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2017.12.002_bib50","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein (a)\u00a0concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","year":"2009","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.ccl.2017.12.002_bib51","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.ccl.2017.12.002_bib52","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ccl.2017.12.002_bib53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jacl.2007.10.001","article-title":"LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management","volume":"1","author":"Cromwell","year":"2007","journal-title":"J\u00a0Clin Lipidol"},{"issue":"7","key":"10.1016\/j.ccl.2017.12.002_bib54","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2017.12.002_bib55","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2014.05.914","article-title":"Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets","volume":"235","author":"Toth","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ccl.2017.12.002_bib56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2017.07.003","article-title":"LDL subfractions are associated with incident cardiovascular disease in the Malm\u00f6 Prevention Project Study","volume":"263","author":"Shiffman","year":"2017","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ccl.2017.12.002_bib57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jacl.2017.05.011","article-title":"Lipoprotein particle number and size predict vascular structure and function better than traditional lipids in\u00a0adolescents and young adults","volume":"11","author":"Urbina","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"issue":"9","key":"10.1016\/j.ccl.2017.12.002_bib58","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-142-9-200505030-00009","article-title":"Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study","volume":"142","author":"Tzou","year":"2005","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ccl.2017.12.002_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between LDL cholesterol and LDL particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J\u00a0Clin Lipidol"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865117301522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865117301522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T17:09:08Z","timestamp":1604077748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865117301522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0733865117301522"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2017.12.002","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipids and Lipoproteins in Risk Prediction","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}